Printer Friendly

Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Hawk Corporation with a Market Outperform Rating; Analyst Sets 12-Month Target Price of $18.00.

NEW YORK -- Rodman & Renshaw, LLC initiated research coverage of Hawk Corporation (ASE: HWK) with a Market Outperform Rating and a 12-month price target $18.00. Joe Giamichael, Senior Industrial Services Analyst, issued the report.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a privately held, full-service investment bank committed to fostering the long-term success of growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. More information is available at www.rodmanandrenshaw.com

None of the research analysts or the research analyst's household has a financial interest in the securities of Hawk Corporation (including, without limitation, any option, right, warrant, future, long or short position).

As of June 30, 2006, neither Rodman & Renshaw, LLC nor its affiliates beneficially own 1% or more of any class of common equity securities of Hawk Corporation.

Neither the research analyst nor Rodman & Renshaw, LLC has any material conflict of interest with Hawk Corporation, of which the research analyst knows or has reason to know at the time of publication of this research report.

Rodman & Renshaw, LLC or its affiliates did not receive compensation from Hawk Corporation for investment banking services within the last twelve months and Rodman & Renshaw, LLC intends to seek compensation from Hawk Corporation for investment banking services within three months, following publication of the research report.

Neither the research analyst nor any member of the research analyst's household nor Rodman & Renshaw, LLC serves as an officer, director or advisory board member of Hawk Corporation.

Rodman & Renshaw, LLC does not make a market in Hawk Corporation securities as of the date of this research report.

The above information is not intended to be used as a primary basis of investment decisions. It is not a representation by Rodman & Renshaw, LLC or an offer or the solicitation of an offer to buy any security. Before investing in Hawk Corporation, you should carefully consider your risk tolerance and financial objectives.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 19, 2006
Words:320
Previous Article:Sequence Clock Power, Voltage Island Analysis Bests Competition; Simplifies Tricky Analysis and Optimization While Chopping Up To 40% Off Power...
Next Article:iPass Positioned in Leaders Quadrant for 2006 Managed Remote Access and Mobility Services Magic Quadrant; Top Analyst Firm Positions iPass in Leaders...
Topics:


Related Articles
Rodman & Renshaw, LLC Announces Investment Opinion on Halozyme Therapeutics, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Javelin Pharmaceuticals, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Cephalon, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Myriad Genetics, Inc.
Rodman & Renshaw, LLC Announces Investment Opinion on Pharmacyclics.
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Advanced Life Sciences Holdings, Inc. With A Market...
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Cytogen Corporation With A Market Outperform Rating.
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of PDG Environmental, Inc. with a Market Outperform...
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Avalon Pharmaceuticals, Inc. With A Market Outperform...
Rodman & Renshaw, LLC Initiates Coverage of Accentia Biopharmaceuticals With A Market Outperform Rating.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters